Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  2006-11-07

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/pnas.0606509103PMID 17077147PMCID PMC1629087
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.

  2006cited by this paper
• Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

  2006cited by this paper
• Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

  2005cited by this paper
• Punish the parent not the progeny.

  2005cited by this paper
• Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.

  2004cited by this paper
• Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia

  2004cited by this paper
• Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor

  2004cited by this paper
• Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.

  2004cited by this paper
• Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases.

  2003cited by this paper
• BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

  2003cited by this paper
• Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr–Abl signal transduction and oncogenesis

  2002cited by this paper
• Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation.

  2002cited by this paper
• Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.

  2002cited by this paper
• Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop

  2002cited by this paper
• Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies.

  2002cited by this paper
• Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

  2001cited by this paper
• Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

  2001cited by this paper
• Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571.

  2001cited by this paper
• Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

  2001cited by this paper
• Tyrosine phosphorylation of Grb2 by Bcr/Abl and epidermal growth factor receptor: a novel regulatory mechanism for tyrosine kinase signaling

  2001cited by this paper
• The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase.

  2001cited by this paper
• The tyrosine kinase inhibitor STI571, like interferon-α, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia

  2000cited by this paper
• The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia.

  2000cited by this paper
• The P190, P210, and P230 Forms of the BCR/ABL Oncogene Induce a Similar Chronic Myeloid Leukemia–like Syndrome in Mice but Have Different Lymphoid Leukemogenic Activity

  1999cited by this paper
• Efficient and Rapid Induction of a Chronic Myelogenous Leukemia-Like Myeloproliferative Disease in Mice Receiving P210 bcr/abl-Transduced Bone Marrow

  1998cited by this paper
• Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.

  1998cited by this paper
• Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo

  1996cited by this paper
• Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia.

  1995cited by this paper
• Absence of the human retinoblastoma gene product in the megakaryoblastic crisis of chronic myelogenous leukemia.

  1991cited by this paper
• p53 in chronic myelogenous leukemia in acute phase.

  1991cited by this paper
• A tail of two src's: mutatis mutandis.

  1987cited by this paper

• A comprehensive prognostic and immune analysis of LAPTM4B in pan-cancer and Philadelphia chromosome-positive acute lymphoblastic leukemia

  2025cites this paper
• Transcriptomic analysis delineates potential regulatory network as therapeutic alternatives in chronic myeloid leukemia

  2024cites this paper
• TSPAN32 suppresses chronic myeloid leukemia pathogenesis and progression by stabilizing PTEN

  2023cites this paper
• PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity

  2023cites this paper
• Targeting BCR-ABL1-positive leukaemias: a review article

  2023cites this paper
• HDAC I/IIb selective inhibitor Purinostat Mesylate combined with GLS1 inhibition effectively eliminates CML stem cells

  2022cites this paper
• YBX1 regulates the survival of chronic myeloid leukemia stem cells by modulating m^6A-mediated YWHAZ stability

  2022cites this paper
• The differential role of the lipid raft-associated protein flotillin 2 for progression of myeloid leukemia

  2022cites this paper
• Arachidonate 15-lipoxygenase is required for chronic myeloid Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival leukemia stem cell survival Let us know how access to this document benefits you.

  2022cites this paper
• The Downregulation of Both Giant HERCs, HERC1 and HERC2, Is an Unambiguous Feature of Chronic Myeloid Leukemia, and HERC1 Levels Are Associated with Leukemic Cell Differentiation

  2022cites this paper
• Dasatinib and interferon alpha synergistically induce pyroptosis-like cell death in philadelphia chromosome positive acute lymphoblastic leukemia.

  2022cites this paper
• Novel pyrazolo[3,4-d]pyrimidines as dual Src/Bcr-Abl kinase inhibitors: Synthesis and biological evaluation for chronic myeloid leukemia treatment.

  2022cites this paper
• Dual Kinase Targeting in Leukemia

  2021cites this paper
• The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13.

  2021cites this paper
• Potential functions of hsa-miR-155-5p and core genes in chronic myeloid leukemia and emerging role in human cancer: A joint bioinformatics analysis.

  2021cites this paper
• Anticancer Activity and Molecular Mechanism of Momordica cochinchinensis Seed Extract in Chronic Myeloid Leukemia Cells

  2021cites this paper
• Dasatinib does not exacerbate dexamethasone‐induced osteonecrosis in murine models of acute lymphoblastic leukemia therapy

  2021cites this paper
• An aging mouse model of human chronic myeloid leukemia

  2021cites this paper
• Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia

  2020influential citation
• GO Nanosheets: Promising Nano Carrier for the S29, 1-(2-Chloro-2-(4-chlorophenyl-ethyl)-N-(4-fluorobenzyl)-1H-pyrazolo[3,4-d] pyrimidin-4-amine, Therapeutic Agent in Neuroblastoma

  2020cites this paper
• Integrin α6 mediates drug resistance of acute lymphoblastic B-cell leukemia.

  2020cites this paper
• Leukemia Stem Cells in Chronic Myeloid Leukemia.

  2019cites this paper
• The transcriptional regulator FUBP1 influences disease outcome in murine and human myeloid leukemia

  2019cites this paper
• Cellular and Molecular State of Myeloid Leukemia Stem Cells.

  2019cites this paper
• Exploiting Unique Biological Features of Leukemia Stem Cells for Therapeutic Benefit.

  2019cites this paper
• STAT5: From Pathogenesis Mechanism to Therapeutic Approach in Acute Leukemia.

  2019cites this paper
• γ-Catenin-Dependent Signals Maintain BCR-ABL1+ B Cell Acute Lymphoblastic Leukemia.

  2019cites this paper
• Mitochondrial metabolic study guided by proteomics analysis in hepatocellular carcinoma cells surviving long-term incubation with the highest dose of sorafenib

  2019cites this paper
• Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of BCR-ABL–Induced B-Cell Acute Lymphoblastic Leukemia

  2019cites this paper
• The vascular bone marrow niche influences outcome in chronic myeloid leukemia via the E-selectin - SCL/TAL1 - CD44 axis

  2019cites this paper
• g-Catenin-Dependent Signals Maintain BCR-ABL1 B Cell Acute Lymphoblastic Leukemia

  2019influential citation
• Repurposing dasatinib for diffuse large B cell lymphoma

  2019cites this paper
• Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK‐ERK and NF‐κB pathways in a model of chronic myeloid leukemia

  2018cites this paper
• Multi-Targeted Approach to Treat DrugResistant CML Using Natural Compounds:A Double Edged Sword

  2018cites this paper
• Targeting the Extracellular Signal-Regulated Kinase 5 Pathway to Suppress Human Chronic Myeloid Leukemia Stem Cells

  2018influential citation
• Advances in biology of acute lymphoblastic leukemia (ALL) and therapeutic implications.

  2018cites this paper
• Inhibition of SRC/FAK cue: A novel pathway for the synergistic effect of rosuvastatin on the anti‐cancer effect of dasatinib in hepatocellular carcinoma

  2018cites this paper
• Activation of TRKA receptor elicits mastocytosis in mice and is involved in the development of resistance to KIT-targeted therapy

  2017cites this paper
• PIM-1 kinase inhibitor SMI-4a exerts antitumor effects in chronic myeloid leukemia cells by enhancing the activity of glycogen synthase kinase 3β

  2017cites this paper
• The SCLtTAxBCR-ABL transgenic mouse model closely reflects the differential effects of dasatinib on normal and malignant hematopoiesis in chronic phase-CML patients

  2017cites this paper
• Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine.

  2017influential citation
• Bosutinib as a fourth-line therapy for a patient with T315I-positive lymphoid blastic phase chronic myeloid leukemia: A case report

  2017cites this paper
• TRƯỜNG ĐẠI HỌC SƯ PHẠM TP HỒ CHÍ MINH

  2017cites this paper
• Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.

  2017cites this paper
• 2 From where do Cancer-Initiating Cells Originate ?

  2017cites this paper
• Orphan drug development for targeting chronic myeloid leukemia stem cells

  2016cites this paper
• Resistance to FLT3 Inhibitors

  2016cites this paper
• Nanodrug-Mediated Thermotherapy of Cancer Stem-Like Cells.

  2016cites this paper
• New Mouse Models to Investigate the Efficacy of Drug Combinations in Human Chronic Myeloid Leukemia.

  2016cites this paper
• Targeting Drug Resistance in Chronic Myeloid Leukemia: A Dissertation

  2016influential citation
• Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)‐Resistant CML Lines While Circumventing Pharmacokinetic Liabilities

  2016cites this paper
• Chronic Myelogenous Leukemia- Initiating Cells Require Polycomb Group Protein EZH2.

  2016cites this paper
• Tyrosine Kinase Inhibitors in Ph+ Chronic Myeloid Leukemia Therapy: a Review.

  2016cites this paper
• Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells

  2016influential citation
• GZD824 suppresses the growth of human B cell precursor acute lymphoblastic leukemia cells by inhibiting the SRC kinase and PI3K/AKT pathways

  2016cites this paper
• Distinct GAB 2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL 1

  2016influential citation
• Chronic Myelogenous Leukemia – Initiating Cells Require Polycomb Group Protein EZH 2

  2016cites this paper
• Title TGF-Β-FOXO signalling maintains leukaemia-initiating cells in chronicmyeloid leukaemia

  2016cites this paper
• Targeting of nucleotide-binding proteins by HAMLET—a conserved tumor cell death mechanism

  2016cites this paper
• BCR/ABL can promote CD19+ cell growth but not render them long-term stemness.

  2016cites this paper
• Chronic Myeloid Leukemia (CML) Mouse Model in Translational Research.

  2016cites this paper
• Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1.

  2016cites this paper
• Title Distinct GAB 2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL 1 Permalink

  2016influential citation
• Beyond tyrosine kinase inhibitors: Combinations and other agents.

  2016cites this paper
• Resistance to Tyrosine Kinase Inhibitors

  2016cites this paper
• CML Mouse Model Generated from Leukemia Stem Cells.

  2016cites this paper
• Potential role of Wnt/β-catenin signaling in blastic transformation of chronic myeloid leukemia: cross talk between β-catenin and BCR-ABL

  2016cites this paper
• Dasatinib for acute lymphoblastic leukemia

  2015cites this paper
• Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

  2015cites this paper
• CD150− Side Population Defines Leukemia Stem Cells in a BALB/c Mouse Model of CML and Is Depleted by Genetic Loss of SIRT1

  2015cites this paper
• Chronic Myeloid Leukaemia Stem Cells are sensitive to the pharmacological inhibition of Hypoxia Inducible Factor-1 α

  2015cites this paper
• The Chromatin Regulator CHD8 Is a Context-Dependent Mediator of Cell Survival in Murine Hematopoietic Malignancies

  2015cites this paper
• Hck inhibitors as potential therapeutic agents in cancer and HIV infection.

  2015cites this paper
• Expression levels of bioactive sphingolipid genes in newly diagnosed and drug-resistant chronic myeloid leukemia patients and their impact on the clinical progress

  2015cites this paper
• HSP90 inhibitor AUY922 induces cell death by disruption of the Bcr-Abl, Jak2 and HSP90 signaling network complex in leukemia cells

  2015cites this paper
• Inhibitor Mediated Bcr-Abl Degradation: A Novel Therapeutic Approach for Chronic Myeloid Leukemia

  2015cites this paper
• Role of the microenvironment in maintenance and resistance of leukemic stem cells in Chronic Myelogenous Leukemia. BMP pathway and mechanical forces

  2015influential citation
• The Implication of Cancer Progenitor Cells and the Role of Epigenetics in the Development of Novel Therapeutic Strategies for Chronic Myeloid Leukemia

  2015cites this paper
• Stem Cell Hierarchy and Clonal Evolution in Acute Lymphoblastic Leukemia

  2015cites this paper
• Survival regulation of leukemia stem cells

  2015cites this paper
• Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells.

  2015cites this paper
• AMPK Protects Leukemia-Initiating Cells in Myeloid Leukemias from Metabolic Stress in the Bone Marrow.

  2015cites this paper
• Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL.

  2015cites this paper
• Secondary mutations as mediators of resistance to targeted therapy in leukemia.

  2015cites this paper
• Salarin C inhibits the maintenance of chronic myeloid leukemia progenitor cells

  2015cites this paper
• Dataset Paper DNA Microarray Assay Helps to Identify Functional Genes Specific for Leukemia Stem Cells

  2015cites this paper
• Modification of Gene Expression, Proliferation, and Function of OP9 Stroma Cells by Bcr-Abl-Expressing Leukemia Cells

  2015cites this paper
• Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival.

  2014cites this paper
• Bosutinib: a novel second-generation tyrosine kinase inhibitor.

  2014cites this paper
• Mapping of Apoptin-interaction with BCR-ABL1, and development of apoptin-based targeted therapy

  2014cites this paper
• Combined STAT3 and BCR-ABL1 Inhibition Induces Synthetic Lethality in Therapy-Resistant Chronic Myeloid Leukemia

  2014cites this paper
• IKK-dependent activation of NF-κB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1.

  2014cites this paper
• Current Concepts in Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

  2014cites this paper
• Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia

  2014cites this paper
• Kinase‐Independent Mechanisms of Resistance of Leukemia Stem Cells to Tyrosine Kinase Inhibitors

  2014cites this paper
• Multidrug resistance in chronic myeloid leukemia

  2014cites this paper
• A Statistical Framework for GeneSet Enrichement Analysis based on DNA Methylation and Gene Expression

  2014cites this paper
• ATRA-Induced Cellular Differentiation and CD38 Expression Inhibits Acquisition of BCR-ABL Mutations for CML Acquired Resistance

  2014cites this paper
• leukemogenesis by BCR-ABL1 B contributes to myeloid and lymphoid κ IKK-dependent activation of NF-

  2014cites this paper
• HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation

  2014cites this paper